Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results
Cash Position: Increased to $271.8 million as of December 31, 2023, from $227.8 million the previous year. R&D Expenses: Decreased to $17.2 million in 2023 from $49.3 million in 2022, reflecting compl...